KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Capital Leases (2017 - 2025)

Moderna (MRNA) has disclosed Capital Leases for 8 consecutive years, with $32.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Capital Leases changed N/A to $32.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was $32.0 million, a N/A change, with the full-year FY2024 number at $39.0 million, down 93.22% from a year prior.
  • Capital Leases was $32.0 million for Q2 2025 at Moderna, down from $35.0 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $912.0 million in Q4 2022 to a low of $32.0 million in Q2 2025.
  • A 5-year average of $427.1 million and a median of $575.0 million in 2023 define the central range for Capital Leases.
  • Peak YoY movement for Capital Leases: skyrocketed 444.55% in 2021, then plummeted 93.22% in 2024.
  • Moderna's Capital Leases stood at $599.0 million in 2021, then skyrocketed by 52.25% to $912.0 million in 2022, then crashed by 36.95% to $575.0 million in 2023, then tumbled by 93.22% to $39.0 million in 2024, then fell by 17.95% to $32.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Capital Leases are $32.0 million (Q2 2025), $35.0 million (Q1 2025), and $39.0 million (Q4 2024).